Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPSOUZA, Aline deSCARIM, Caue BenitoCOTRIM, Paulo CesarBARBOSA JUNIOR, FernandoROCHA, Bruno AlvesCALIXTO, Leandro AugustoCORREIA, Cristiano JesusARAUJO, Gabriel Lima de BarrosLOBENBERG, RaimarBOU-CHACRA, Nadia AraciBREITHAUPT-FALOPPA, Ana Cristina2024-04-052024-04-052024NANOMEDICINE, v.19, n.4, p.293-301, 20241743-5889https://observatorio.fm.usp.br/handle/OPI/58893Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 mu g/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.engrestrictedAccesschylomicronscycloheximidehydroxymethylnitrofurazonelymphatic systemnanostructured lipid carrierin-vitrodrug-deliverysystemtransportarticleCopyright FUTURE MEDICINE LTD10.2217/nnm-2023-0263Biotechnology & Applied MicrobiologyNanoscience & Nanotechnology1748-6963